Abstracts tagged "Dermatology"

Abstract Number: 0205 • ACR Convergence 2021
An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study
Ediz Dalkilic¹, Dilek Solmaz², Orhan Kucuksahin³, Erhan Capkin⁴, Mehmet Emin Derin⁵, Didem Arslan⁶, Fatih Noyan⁷, Nihan Belkis Coskun¹, Sadiye Murat⁸, Omer Faruk Sendur⁹, Meltem Alkan Melikoglu¹⁰, Savas Gursoy¹¹, Taciser Kaya¹², Ali Sahin¹³, Murat Karkucak⁴, Timur Pirildar¹⁴, Mustafa Ender Terzioglu¹⁵, Cemal Bes¹⁶ and Servet Akar², ¹Uludag University, School of Medicine – Bursa, Turkey, Bursa, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Ankara State Hospital, School of Medicine, Ankara, Turkey, ⁴Karadeniz Technical University, School of Medicine, Trabzon, Turkey, ⁵Sivas Numune Hospital, Sivas, Turkey, ⁶Cukurova University, School of Medicine – Adana, Turkey, Adana, Turkey, ⁷Nazilli State Hospital – Aydın, Turkey, Aydin, Turkey, ⁸Istanbul Medeniyet University, Goztepe Training and Research Hospital, İstanbul, Turkey, ⁹Adnan Menderes University, School of Medicine, Aydin, Turkey, ¹⁰Ataturk University, School of Medicine, Erzurum, Turkey, ¹¹Gaziantep University, School of Medicine – Gaziantep, Turkey, Gaziantep, Turkey, ¹²Saglik Bilimleri University, Izmır Bozyaka Trainig and Research Hospital – Izmir, Turkey, Izmir, Turkey, ¹³Sivas Cumhuriyet University, School of Medicine, Sivas, Turkey, ¹⁴Celal Bayar University, School of Medicine – Manisa, Turkey, Manisa, Turkey, ¹⁵Akdeniz University, School of Medicine, Antalya, Turkey, ¹⁶Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Available evidence suggests that timely and effective management of patients with psoriatic arthritis (PsA) can improve long-term outcomes. Current information on the factors which…
Abstract Number: 0513 • ACR Convergence 2021
Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood
DeAnna Diaz¹, Thomas Vazquez², Christina Bax³, Jay Patel⁴, Madison Grinnell⁵, Emily Keyes⁶, Yubin Li⁵ and Victoria Werth⁷, ¹Philadelphia College of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Corporal Michael J. Crescenz VAMC/ Department of Dermatology, U Penn, Philadelphia, PA, ⁴Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, ⁵Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, ⁶Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…
Abstract Number: 0706 • ACR Convergence 2021
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Madison Grinnell¹, Emily Keyes², DeAnna Diaz², Thomas Vazquez³, Rui Feng⁴ and Victoria Werth², ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ³FIU Wertheim College of Medicine, Virginia Beach, VA, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Treatment of dermatomyositis (DM) typically follows a stepwise sequence starting with either methotrexate (MTX) or mycophenolate mofetil (MMF) after an inadequate response to antimalarial…
Abstract Number: 1026 • ACR Convergence 2021
Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
Sung Kyung Cho¹, Lorinda Chung² and David Fiorentino³, ¹University of Texas Southwestern, Dallas, TX, ²Stanford University, Palo Alto, CA, ³Stanford University, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…
Abstract Number: 1170 • ACR Convergence 2021
Establishment and Validation of a Didactic Musculoskeletal Ultrasound Course for Dermatologists Using an Innovative Handheld Ultrasound System
Jakub Grobelski¹, Florian Recker², Pantelis Karakostas¹, Dagmar Wilsmann-Theis³, Wolfgang Hartung⁴, Peter Brossart⁵ and Valentin Schäfer¹, ¹Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ²Centre for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Department of Rheumatology and Clinical Immunology, Asklepios Clinic, Bad Abbach, Germany, ⁵Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany
Background/Purpose: In the early detection of arthritis, such as psoriatic arthritis, ultrasound (US) of painful joints plays an important role in diagnosis. Pathological findings can…
Abstract Number: 1178 • ACR Convergence 2021
Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
Mavra Masood, Fnu Nutan, Julia Nunley and Beth Rubinstein, Virginia Commonwealth University, Richmond, VA
Background/Purpose: There is a dearth of resources for medical students on identifying skin findings of autoimmune disorders in skin of color. Considering how several rheumatologic…
Abstract Number: 0849 • ACR Convergence 2020
Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials
Joan Merrill¹, Kenneth Kalunian², Richard Furie³, Kevin Winthrop⁴, Patricia Primakov⁵, Lilia Pineda⁶, Gabriel Abreu⁷ and Raj Tummala⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²School of Health Sciences, University of California, La Jolla, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Oregon Health & Science University, Portland, OR, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 2 MUSE and phase 3 TULIP-1 and TULIP-2 trials, treatment with anifrolumab, a monoclonal antibody to the type I interferon receptor,…
Abstract Number: 1063 • ACR Convergence 2020
Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro
Christina Bax¹, Yubin Li¹, Spandana Maddukuri², Adarsh Ravishankar³, Jay Patel³, Daisy Yan¹, Josef Symon Concha¹ and Victoria Werth¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia
Background/Purpose: Spirulina, a popular herbal supplement, stimulates the immune system, as determined by in vitro and in vivo studies. Our recent epidemiologic data suggest that Spirulina…
Abstract Number: 1404 • ACR Convergence 2020
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Jay Patel¹, Spandana Maddukuri², Yubin Li³, Christina Bax⁴ and Victoria Werth³, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of Pennsylvania, Department of Dermatology, Philadelphia
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
Abstract Number: 1405 • ACR Convergence 2020
Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry
Jay Patel¹, Adarsh Ravishankar¹, Spandana Maddukuri², Christina Bax³ and Victoria Werth⁴, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Antisynthetase syndrome (AS) is a systemic autoimmune disorder characterized by the presence of anti-aminoacyl-tRNA synthetase antibodies, myositis, interstitial lung disease (ILD), mechanics hands, and…
Abstract Number: 1560 • ACR Convergence 2020
Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry
Laila Abbas¹, Jennifer Day² and Heidi Jacobe³, ¹UT Southwestern Medical Center, Dallas, TX, ²University of Colorado, Denver, CO, ³University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Morphea is an autoimmune disorder causing sclerosis and inflammation of the skin and subcutaneous tissue. Facial morphea can cause substantial disfigurement and negative impact on quality of life. Existing clinical measures such…
Abstract Number: 1594 • ACR Convergence 2020
Hydroxychloroquine Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool², Christopher Hansen² and Dorota Lebiedz-Odrobina², ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: One rare but devastating adverse event related to the use of hydroxychloroquine (HCQ) is retinal toxicity. Retinal toxicity rates from HCQ can be as…
Abstract Number: 1982 • ACR Convergence 2020
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Josef Symon Concha¹, Daisy Yan¹, Christina Bax², Adarsh Ravishankar³, Robert Borucki⁴, Rui Feng⁴ and Victoria Werth⁵, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
Abstract Number: 1988 • ACR Convergence 2020
Skin Disease More Recalcitrant to Intervention Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis
Andi Wang¹, Gabrielle Morgan², Chiang-Ching Huang³, Amy Paller⁴ and Lauren Pachman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Joseph J. Zilber School of Public Health, Milwaukee, ⁴Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, ⁵Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL
Background/Purpose: Persistent skin manifestations, in particular calcinosis, contribute to significant morbidity in patients with JDM. The goal of this study was to compare the course…
Abstract Number: 2037 • ACR Convergence 2020
Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts
Anastasiya Muntyanu¹, Bina Kassamali², Ruth Ann Vleugels³ and Avery LaChance³, ¹McGill University, Montreal, QC, Canada, ²Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune sclerosing disease with a 10-year survival rate of less than 65%. This rate has remained unchanged for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].